Scientists at the University of Leeds have developed a device that avoids the constant finger pricks in hyperglycemic patients.
A no-prick blood glucose monitoring device developed by researchers at the University of Leeds could prove to be a boon for diabetic patients the world over. The development of this continuous monitoring device has now been licensed to Glucosense Diagnostics, a spin-off of the University of Leeds and a biomedical and healthcare technology group NetScientific plc, which helps commercialize academic discoveries and inventions.
The credit for this device development goes to the collaborative efforts between a materials scientist, Professor Gin Jose at the University of Leeds, and a clinician, Professor Peter Grant, at the Leeds Institute of Cardiovascular and Metabolic Medicine, who conducted a pilot clinical trial to test the device. The pilot showed that the device matches-up with existing conventional technologies.
According to a report in ScienceDaily, at the center of the device is a piece of nano-engineered silica glass with ions that fluoresce in infrared light when a low power laser light hits them. When the glass is in contact with the users' skin, the extent of fluorescence signal varies in relation to the concentration of glucose in their blood. The device measures the length of time the fluorescence lasts for and uses that to calculate the glucose level in a person's bloodstream without the need for a needle—a process that lasts less than 30 seconds.
The advantage of this potentially wearable technology, in addition to its obvious ease of use, is that it is pain free, does not require implants, and could reduce wastage by eliminating the need for needles and sample strips. Although the company claims the device is cost-effective, that remains to be seen. If it improves self-management as it claims, the device could help control wide fluctuations in glucose levels and also reduce physician visits and healthcare utilization.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More